Placental transfer and DNA binding of benzo(a)pyrene in human placental perfusion

Toxicology Letters

Volumn 197, Issue 2, 2010, Pages 75-81

  Karttunen, Vesa ^a   Myllynen, Päivi ^b   Prochazka, Gabriela ^c   Pelkonen, Olavi ^b   Segerbäck, Dan ^c   Vähäkangas, Kirsi ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ABCB1 P glycoprotein; BeWo cells; BPDE DNA adducts; EROD activity; Placental xenobiotic metabolism

Indexed keywords

BENZO[A]PYRENE; BENZO[A]PYRENE 7,8 DIHYDRODIOL 9,10 OXIDE; ETHOXYRESORUFIN DEETHYLASE; MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL;

ARTICLE; CARCINOGEN DNA INTERACTION; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FETUS CIRCULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MATERNAL BLOOD; PLACENTAL TRANSFER; PRENATAL EXPOSURE; PRIORITY JOURNAL; TROPHOBLAST;

BENZO(A)PYRENE; CELL LINE, TUMOR; CHORIOCARCINOMA; CYTOCHROME P-450 CYP1A1; DNA; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; PERFUSION; PLACENTA; PREGNANCY; TIME FACTORS;

EID: 77953962137     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.04.028     Document Type: Article

References (58)

1. AlaKokko T.I., Pienimäki P., Herva R., Hollmén A.I., Pelkonen O., Vähäkangas K. Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. Pharmacol. Toxicol. 1995, 77:142-145.
2. Annola K., Karttunen V., Keski-Rahkonen P., Myllynen P., Segerbäck D., Heinonen S., Vähäkangas K. Transplacental transfer of acrylamide and glycidamide are comparable to that of antipyrine in perfused human placenta. Toxicol. Lett. 2008, 182:50-56.
3. Avery M.L., Meek C.E., Audus K.L. The presence of inducible cytochrome P450 types 1A1 and 1A2 in the BeWo cell line. Placenta 2003, 24:45-52.
4. Baird W.M., Hooven L.A., Mahadevan B. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ. Mol. Mutagen. 2005, 45:106-114.
5. Barr D.B., Bishop A., Needham L.L. Concentrations of xenobiotic chemicals in the maternal-fetal unit. Reprod. Toxicol. 2007, 23:260-266.
6. Bassily M., Ghabrial H., Smallwood R.A., Morgan D.J. Determinants of placental drug transfer: studies in the isolated perfused human placenta. J. Pharm. Sci. 1995, 84:1054-1060.
7. Benirschke K., Kaufmann P., Baergen R.N. Pathology of the Human Placenta 2006, Springer Science+Business Media, New York. fifth ed.
8. Benowitz N.L. Antihypertensive agents. Basic & Clinical Pharmacology 1995, 147-170. Prentice Hall International, London. sixth ed. B.G. Katzung (Ed.).
9. Burke M.D., Prough R.A., Mayer R.T. Characteristics of a microsomal cytochrome P-448-mediated reaction: ethoxyresofurin O-deethylation. Drug Metab. Dispos. 1977, 5:1-8.
10. Castellucci M., Kaufmann P. Basic structure of the villous trees. Pathology of the Human Placenta 2006, 50-99. Springer Science+Business Media, New York. fifth ed. K. Benirschke, P. Kaufmann, R.N. Baergen (Eds.).
11. Dybing E., OóBrien J., Renwick A.G., Sanner T. Risk assessment of dietary exposures to compounds that are genotoxic and carcinogenic-an overview. Toxicol. Lett. 2008, 180:110-117.
12. Frey-Hattemer H.A., Travis C.C. Benzo-a-pyrene: environmental partitioning and human exposure. Toxicol. Ind. Health 1991, 7:141-157.
13. Ganapathy V., Prasad P.D. Role of transporters in placental transfer of drugs. Toxicol. Appl. Pharmacol. 2005, 207:381-387.
14. Grant S.G. Qualitatively and quantitatively similar effects of active and passive maternal tobacco smoke exposure on in utero mutagenesis at the HPRT locus. BMC Pediatr. 2005, 5:20.
15. Hakkola J., Pelkonen O., Pasanen M., Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit. Rev. Toxicol. 1998, 28:35-72.
16. Huuskonen P., Storvik M., Reinisalo M., Honkakoski P., Rysä J., Hakkola J., Pasanen M. Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin. Pharmacol. Ther. 2008, 83:542-550.
17. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., Schinkel A.H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 2000, 92:1651-1656.
18. Kihlström I. Placental transfer of benzo(a)pyrene and its hydrophilic metabolites in the guinea pig. Acta Pharmacol. Toxicol. 1986, 58:272-276.
19. Kim R.B. Drugs as p-glycoprotein substrates, inhibitors and inducers. Drug Metab. Rev. 2002, 34:47-54.
20. Kruger N.J. The Bradford method for protein quantitation. Methods Mol. Biol. 1994, 32:9-15.
21. Lagerqvist A., Håkansson D., Prochazka G., Lundin C., Dreij K., Segerbäck D., Jernström B., Törnqvist M., Seidel A., Erixon K., Jenssen D. Both replication bypass fidelity and repair efficiency influence the yield of mutations per target dose in intact mammalian cells induced by benzo[a]pyrene-diol-epoxide and dibenzo[a,l]pyrene-diol-epoxide. DNA Repair 2008, 7:1202-1212.
22. Lankas G.R., Wise L.D., Cartwright M.E., Pippert T., Umbenhauer D.R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 1998, 12:457-463.
23. Lee B.M., Shim G.A. Dietary exposure estimation of benzo[a]pyrene and cancer risk assessment. J. Toxicol. Environ. Health A 2007, 70:1391-1394.
24. Manchester D.K., Bowman E.D., Parker N.B., Caporaso N.E., Weston A. Determinants of polycyclic aromatic hydrocarbon-DNA adducts in human placenta. Cancer Res. 1992, 52:1499-1503.
25. Mao Q. BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm. Res. 2008, 25:1244-1255.
26. Mathiesen L., Rytting E., Mose T., Knudsen L.E. Transport of benzo[alpha]pyrene in the dually perfused human placenta perfusion model: effect of albumin in the perfusion medium. Basic Clin. Pharmacol. Toxicol. 2009, 105:181-187.
27. Miller K.P., Ramos K.S. Impact of cellular metabolism on the biological effects of benzo(a)pyrene and related hydrocarbons. Drug Metab. Rev. 2001, 33:1-35.
28. Myllynen P., Pienimäki P., Raunio H., Vähäkangas K. Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Hum. Exp. Toxicol. 1998, 17:668-676.
29. Myllynen P.K., Pienimäki P.K., Vähäkangas K.H. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol. 2003, 58:677-682.
30. Myllynen P., Pasanen M., Vähäkangas K. The fate and effects of xenobiotics in human placenta. Expert Opin. Drug Metab. Toxicol. 2007, 3:331-346.
31. Pacifici G.M., Nottoli R. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 1995, 28:235-269.
32. Pelkonen O., Nebert D.W. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol. Rev. 1982, 34:189-222.
33. Pelkonen O., Vähäkangas K., Kärki N.T., Sotaniemi E.A. Genetic and environmental regulation of aryl hydrocarbon hydroxylase in man: studies with liver, lung, placenta, and lymphocytes. Toxicol. Pathol. 1984, 12:256-260.
34. Perera F.P. Environment and cancer: who are susceptible?. Science 1997, 278:1068-1073.
35. Perera F.P., Jedrychowski W., Rauh V., Whyat R.M. Molecular epidemiologic research on the effects of environmental pollutants on the fetus. Environ. Health Perspect. 1999, 107:451-460.
36. Perera F., Hemminki K., Jedrychowski W., Whyatt R., Campbell U., Hsu Y., Santella R., Albertini R., O'Neill J.P. In utero DNA damage from environmental pollution is associated with somatic gene mutation in newborns. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1134-1137.
37. Perera F.P., Rauh V., Whyatt R.M., Tang D., Tsai W.Y., Bernert J.T., Tu Y.H., Andrews H., Barr D.B., Camann D.E., Diaz D., Dietrich J., Reyes A., Kinney P.L. A summary of recent findings on birth outcomes and developmental effects of prenatal ETS, PAH, and pesticide exposures. Neurotoxicology 2005, 26:573-587.
38. Phillips D.H., Castegnaro M. Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 1999, 14:301-315.
39. Phillips D.H. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002, 23:1979-2004.
40. Pienimäki P., Hartikainen A.L., Arvela P., Partanen T., Herva R., Pelkonen O., Vähäkangas K. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 1995, 36:241-248.
41. Pienimäki P., Lampela E., Hakkola J., Arvela P., Raunio H., Vähäkangas K. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997, 38:309-316.
42. 6-substituted adenine and 3-substituted cytosine/uracil: formation and persistence in vitro and in vivo. Carcinogenesis 1999, 20:2025-2032.
43. Pyy L., Mäkelä M., Hakala E., Kakko K., Lapinlampi T., Lisko A., Yrjänheikki E., Vähäkangas K. Ambient and biological monitoring of exposure to polycyclic aromatic hydrocarbons at a coking plant. Sci. Total Environ. 1997, 199:151-158.
44. 32P-postlabeling assay based on the specific enzymatic conversion of bulky DNA lesions to radiolabeled dinucleotides and nucleoside 5'-monophosphates. Carcinogenesis 1989, 10:1231-1239.
45. Schneider H., Panigel M., Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 1972, 114:822-828.
46. Schuetz E.G., Yasuda K., Arimori K., Schuetz J.D. Human MDR1 and mouse mdr1a p-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch. Biochem. Biophys. 1998, 350:340-347.
47. Smit J.W., Huisman M.T., van Tellingen O., Wiltshire H.R., Schinkel A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 1999, 104:1441-1447.
48. Straif K., Baan R., Grosse Y., Secretan B., El G.F., Cogliano V. Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol. 2005, 6:931-932.
49. Syme M.R., Paxton J.W., Keelan J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 2004, 43:487-514.
50. Tang D., Li T.Y., Liu J.J., Chen Y.H., Qu L., Perera F. PAH-DNA adducts in cord blood and fetal and child development in a Chinese cohort. Environ. Health Perspect. 2006, 114:1297-1300.
51. Topinka J., Milcova A., Libalova H., Novakova Z., Rossner P., Balascak I., Sram R.J. Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. Part I. Bulky DNA adducts. Mutat. Res. 2009, 669:13-19.
52. Vähäkangas K., Haugen A., Harris C.C. An applied synchronous fluorescence spectrophotometric assay to study benzo[a]pyrene-diolepoxide-DNA adducts. Carcinogenesis 1985, 6:1109-1115.
53. Vähäkangas K., Raunio H., Pasanen M., Sivonen P., Park S.-S., Gelboin H., Pelkonen O. Comparison of the formation of benzo(a)pyrene diolepoxide-DNA adducts in rat and human tissues. Evidence for the involvement of cytochrome P450IA1. J. Biochem. Toxicol. 1989, 4:79-86.
54. Vähäkangas K., Myllynen P. Drug transporters in the human blood-placental barrier. Br. J. Pharmacol. 2009, 158:665-678.
55. Wang S., Chanock S., Tang D., Li Z., Jedrychowski W., Perera F.P. Assessment of interactions between PAH exposure and genetic polymorphisms on PAH-DNA adducts in African, American, Dominican, and Caucasian mothers and newborns. Cancer Epidemiol. Biomarkers Prev. 2008, 17:405-413.
56. Wogan G.N., Hecht S.S., Felton J.S., Conney A.H., Loeb L.A. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 2004, 14:473-486.
57. Yeh G.C., Lopaczynska J., Poore C.M., Phang J.M. A new functional role for p-glycoprotein: efflux pump for benzo(a)pyrene in human breast cancer MCF-7 cells. Cancer Res. 1992, 52:6692-6695.
58. Zhang L., Connor E.E., Chegini N., Shiverick K.T. Modulation by benzo[a]pyrene of epidermal growth factor receptors, cell proliferation, and secretion of human chorionic gonadotropin in human placental cells. Biochem. Pharmacol. 1995, 50:1171-1180.